Pivotal bioVenture Partners China

Heranova Lifesciences is a company focused on providing innovative solutions for women's health, specifically in the fields of obstetrics and gynecology. It develops advanced medical technologies that address unmet needs related to women's health issues. By integrating diagnostics, pharmaceuticals, medical devices, and data, Heranova Lifesciences aims to facilitate the early development of innovative treatments for conditions such as endometriosis and gynecological inflammation. This comprehensive approach enables the company to effectively respond to the unique challenges faced by women in managing their health.

Ablaze Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing Targeted Radiotherapy (TRT) treatments aimed at benefiting cancer patients. The company focuses on innovative TRT products, utilizing the extensive business experience and networks of its founders in cross-border product development and deal-making. By targeting the Chinese market, Ablaze Pharmaceuticals seeks to provide effective cancer treatment options tailored to the needs of patients in the region.

Arctic Vision is a clinical-stage specialty ophthalmology company based in China, focused on developing innovative therapies to meet the unmet clinical needs in ophthalmic diseases. The company boasts a leading portfolio of breakthrough technologies aimed at addressing various eye care challenges in China, Asia, and globally. Established by prominent life sciences investors, Arctic Vision is guided by a team of experienced professionals from the ophthalmic industry, who possess extensive knowledge in research and development as well as commercialization of eye care products. The company's efforts include the development of new ophthalmic medicines, particularly gene therapies, that hold significant commercial potential and aim to improve the recovery outcomes for patients with rare ophthalmic conditions.

Visen Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for endocrine diseases, addressing significant unmet medical needs in China. The company emphasizes patient-centric care, aiming to provide first-in-class or best-in-class treatments for both common and rare endocrine disorders affecting adults and children. With a team of experienced professionals from multinational pharmaceutical backgrounds, Visen leverages advanced technologies and resources to enhance its operations. The company has established a strong presence in the Chinese market, with offices in Shanghai, Beijing, Hong Kong, and Taipei, as well as a research and manufacturing site in Suzhou. This strategic setup aims to accelerate the availability of advanced treatment solutions for endocrine patients in China.

Arctic Vision is a clinical-stage specialty ophthalmology company based in China, focused on developing innovative therapies to meet the unmet clinical needs in ophthalmic diseases. The company boasts a leading portfolio of breakthrough technologies aimed at addressing various eye care challenges in China, Asia, and globally. Established by prominent life sciences investors, Arctic Vision is guided by a team of experienced professionals from the ophthalmic industry, who possess extensive knowledge in research and development as well as commercialization of eye care products. The company's efforts include the development of new ophthalmic medicines, particularly gene therapies, that hold significant commercial potential and aim to improve the recovery outcomes for patients with rare ophthalmic conditions.

OncXerna Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for cancer patients by utilizing an RNA-based biomarker platform. The company aims to improve patient outcomes by prospectively identifying individuals based on the unique RNA biology of their tumor microenvironments. This innovative approach enables OncXerna to match patients with targeted oncology therapies that correspond to their specific tumor characteristics. Founded in 2018 and based in Waltham, Massachusetts, with an additional location in Shanghai, China, OncXerna was formerly known as Oncologie, Inc. and changed its name in September 2020 to reflect its commitment to advancing next-generation precision medicine for a broader range of cancer patients.

OncXerna Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for cancer patients by utilizing an RNA-based biomarker platform. The company aims to improve patient outcomes by prospectively identifying individuals based on the unique RNA biology of their tumor microenvironments. This innovative approach enables OncXerna to match patients with targeted oncology therapies that correspond to their specific tumor characteristics. Founded in 2018 and based in Waltham, Massachusetts, with an additional location in Shanghai, China, OncXerna was formerly known as Oncologie, Inc. and changed its name in September 2020 to reflect its commitment to advancing next-generation precision medicine for a broader range of cancer patients.